l-alanyl l-glutamine + fluorouracil + oxaliplatin

This is a combination regimen consisting of three agents: - **L-alanyl L-glutamine** is a dipeptide used as a stable source of glutamine, often administered to support nutritional status and intestinal mucosal integrity during chemotherapy. - **Fluorouracil (5-FU)** is an antimetabolite chemotherapeutic agent that inhibits thymidylate synthase, thereby interfering with DNA synthesis and function. - **Oxaliplatin** is a platinum-based chemotherapeutic that forms DNA crosslinks, inhibiting DNA replication and transcription. The combination of fluorouracil and oxaliplatin (often with leucovorin) is well-established in the treatment of colorectal cancer, particularly in regimens such as FOLFOX. The addition of L-alanyl L-glutamine may be intended to reduce gastrointestinal toxicity or improve patient tolerance during chemotherapy. The primary mechanism involves cytotoxic effects on rapidly dividing tumor cells through inhibition of DNA synthesis (fluorouracil) and induction of DNA damage (oxaliplatin). This regimen targets advanced or metastatic colorectal cancer but may also be explored for other gastrointestinal malignancies[2][6][7].